Doug Drysdale

Boston, Massachusetts, USA

https://www.cybin.com/

In his 30-year career as a leader and entrepreneur, Drysdale has led hundreds of biopharma business development transactions, closed 15 M&A transactions around the world, created a $500mm startup, co-founded a CNS development company, developed pipelines of pharmaceutical products, and has led both private and public companies. In September 2020, he was appointed to CEO of psychedelics-focused life sciences company...

Cybin posts second-quarter loss widens as clinical trials advance

Toronto-based Cybin Inc. (NYSE: CYBN) reported financials for its fiscal second quarter 2025 ending Sept. 30, with higher R&D costs from its clinical programs. The...

FDA Talks Help Cybin Advance Two Psychedelic Drugs Toward Approval - Clinical Leader

Cybin CEO Doug Drysdale discusses regulatory considerations relating to the pursuit of two different psychedelic drugs and talks about trends in ...

Cybin reports strong cash reserves amid rising R&D costs in Q3

Clinical-stage biopharmaceutical Toronto-based Cybin Inc. (NYSE: CYBN) reported its financial outcomes for the third quarter ending December 31, 2023. The company said that its cash...

Cybin Acquires Small Pharma in All-Share Deal

Toronto-based Cybin Inc. and UK-based Small Pharma Inc. have announced a definitive agreement for Cybin to acquire all outstanding securities of Small Pharma in an...

Unleashing the Potential of Psychedelic Science with Kernel Flow

Psychedelics made their official debut in the Western world over half a century ago. However, there are still a lot of unknowns. The large gap...

Cybin Announces Phase 2 Dosing Completion of CYB003 Trial (Cohort 5)

For more on Cybin, see our interview with CEO Doug Drysdale View this post on Instagram A post shared by Microdose Psychedelic Insights (@microdosehq) Cybin...

Cybin Posts C$47.5 Million Loss for 2023 Fiscal Year

Toronto-based Cybin Inc. (NEO: CYBN) (NYSE: CYBN) trimmed its losses C$47.5 million in its most recent fiscal year, which ended March 31, compared with C$67.6...

Cybin Posts C$47.5 Million Loss for 2023 Fiscal Year

Toronto-based Cybin Inc. (NEO: CYBN) (NYSE: CYBN) trimmed its losses C$47.5 million in its most recent fiscal year, which ended March 31, compared with C$67.6...

Cybin and The Chopra Foundation to Participate in Featured Session at ... - Yahoo Finance

Cybin CEO, Doug Drysdale and Wellness Icon Deepak Chopra to be featured on panel titled Open Minds: Innovations in Consciousness, Psychedelics ...

Cybin Cuts 15% of Staff as Part of ‘Streamlining Plan’

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) slashed 15% of its workforce as part of a “streamlining plan” as the biopharmaceutical company realigns to increase...

Cybin Maintains Steady Runway, Finds Approval for DMT and Psilocybin Studies

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) made strides in its active branded drug programs looking to treat anxiety and major depressive disorders. The Toronto-based...

VIDEO Interview: A Psychedelic Conversation with Doug Drysdale, CEO of Cybin

In this interview, Adam Tubero and Doug Drysdale get into all things Cybin ($CYBN) including amorphous psilocybin, deuterated DMT, CYB003, and much more. Stay Tuned...

The Real Reason Cybin Bought Entheon's DMT Clinical Trial | Psychedelic Spotlight

Recently, I had the opportunity to ask Cybin's CEO Doug Drysdale about the purchase in an AMA —Ask Me Anything— hosted by Psychedelic Spotlight. While ...

Cybin Submits IND to FDA for Phase 1/2a Trial of CYB003

Back in November 2021, Cybin made headlines by announcing that they were switching lead candidate drugs — from CYB-001 to CYB-003. The announcement, made at...

Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog

Cybin CEO Doug Drysdale stated, “Based on preclinical studies, our proprietary psilocybin analog has the potential to offer numerous advantages over ...

Cybin

CEO

Last updated: Dec 14, 2022

Request Deletion